Highlights {#s1}
==========

-   STZ induced diabetic rats displayed renal tubular damage and glomerular injury as evident by increased FBG, BUN, 24 h urea protein and increase in renal hypertrophy index.

-   SA pretreatment prevents renal tubular oxidative stress, inflammation, and apoptosis in diabetic rats.

-   SA pretreatment inhibits apoptosis in renal tubules by downregulating apoptotic protein caspase 3, Bax and upregulating anti-apoptotic protein Bcl-2.

-   SA pretreatment modulates the Nrf2/HO-1 pathway to upregulate and anti-oxidant defense enzymes SOD, GPX, and catalase in diabetic rats.

Introduction {#s2}
============

Diabetes mellitus (DM) is a diversely complicated disease of insulin dysfunction often associated with dreadful repercussion by hyperglycemia, hypoinsulinemia, and glycosuria. Diabetes mellitus (DM) encapsulates a variety of severe metabolic diseases distinguished by hyperglycemia, hypoinsulinemia, and glycosuria. DM is a multifaceted syndrome comprising insulin impairment along with glucose steady state and lipid metabolism abnormalities. Moreover, the parallel high level of blood glucose and (or) low insulin conditions, ultimately, might have serious injurious consequences on the body physiology ([@B24]). Therefore, DM is a major threat to public health and its prevalence is increasing as this disease can cause long-lasting impairments of physiological functions and failures in organs with widespread impediments ([@B39]; [@B55]). For instance, 40% of end stage renal disease (ESRD) cases in diabetic patients because of diabetic nephropathy ([@B34]). Due to hyperglycemia, there might be numerous toxicity effects that can occur in diabetic patients at the physiological and metabolic levels. This would lead to unpleasant consequences, as a result of hyperglycemia, such as infections, promoting cancers, proteins modification, and many other concerns. Therefore, the management of hyperglycemia remains the primary goal in DN therapy ([@B22]). The oral hypoglycemic agents used in the management therapies for DM must improve the pathophysiology by increasing insulin secretion and/or sensitivity, as well as inhibit hepatic glucose production *via* the downregulation of gluconeogenesis ([@B15]; [@B80]; [@B46]; [@B47]). The oral hypoglycemic agents used to alleviate DN are adipogenic ([@B33]), and synthetic oral hypoglycemic therapies are closely associated with various toxicities ([@B63]). DM can be managed by oral hypoglycemic agents and insulin, but these approaches fail to clinically reinstate normoglycemia in most patients ([@B56]). The World Health Organization (WHO) endorses the use of herbs or natural products for the management of DM as trustworthy with few or no side effects. In fact, these natural products are deliberated as good contenders for oral therapy ([@B60]). Prolonged hyperglycemia persuades the accumulation of reactive oxygen species (ROS) ([@B45]), and excessive ROS production inflicts tissue injuries ([@B21]). Various factors contribute to the progression of DN, including hyperglycemia, glycosuria, hypertension, ketoacidosis, coronary heart disease, obesity, and advancing age, but the exact mechanism remains elusive ([@B7]). Notably, the progression of DN is linked with oxidative stress and inflammation ([@B78]). Moreover, ROS is critically involved in the progression of DN ([@B65]). The transcription factor, nuclear factor erythroid 2-like 2 (Nrf2), is a major mediator controlling redox enzymes defense systems in reaction to oxidative stress. Nrf2 is seized in the cytoplasm *via* its binding to Kelch-like ECH-associated protein 1 (Keap1) ([@B26]). Oxidative stress encourages translocation of Nrf2 to the nucleus, where it upregulates the antioxidant defense enzymes and heme oxygenase-1 (HO-1) ([@B42]; [@B52]). The enhancement of ROS levels, including superoxides and hydrogen peroxide, in DN has been reported ([@B53]). Nrf2 impairment in DN causes accumulation of peroxide radicals inflicting renal tissues injuries ([@B41]). Hence, the improvement (i.e. upregulation) of Nrf2/HO-1 has been gaining popularity as a therapeutic approach. Several Nrf2 activating natural polyphenols have been reported to ameliorate DN in patients ([@B69]; [@B81]; [@B82]). SA (3,5-dimethoxy-4-hydroxycinnamic acid), that can be found in berries, vegetables, cereals, and oilseed crops ([@B2]), is naturally phenolic compound that can be found in the plant such as fruits, vegetables, cereal grains, and oilseed crops. The list of the medicational effects of SA covers different pharmacological activities such as possesses antioxidant, antidiabetic, anti-inflammatory, anticancer, antimicrobial, antihypertensive, and anxiolytic activities ([@B43]; [@B30]; [@B11]; [@B64]). SA has a potent chemoprotective effect due to its free radical-scavenging activity that protects against tissue injury ([@B59]; [@B11]; [@B10]; [@B62]). Sinapic acid significantly decrease lipid peroxidation marker TBARS and increases the antioxidants markers like SOD, CAT, GPx, and GSH in serum, liver, and kidney in diabetic rats ([@B29]). Although effect of SA on the biochemical markers (such as blood urea, serum creatinine, uric acid, and FBG) have been investigated previously ([@B15]; [@B29]; [@B80]; [@B46]; [@B47]), we here investigating the effect of SA on the gene expression of SOD, GPx, and catalase and the signaling pathway of Nrf2/HO-1 in the STZ-induced DN rats. Thus, high potential of sinapic acid pharmacological activities in diabetic models has instigated us to postulate that SA upregulates Nrf2 nuclear translocation and HO-1 expression. Furthermore, we anticipated that SA activates the Nrf2/HO-1 antioxidant pathway in STZ-induced DN rats.

Materials and Methods {#s3}
=====================

Chemicals {#s3_1}
---------

STZ, SA, GPx, sodium azide, and thiobarbituric acid were obtained from the same vendor (Sigma Chemicals Co, St. Louis, MO, USA). Antibodies against Nrf2, NF-kB (p65), HO-1, HRP-conjugated secondary antibodies, and β-actin were obtained from Santa Cruz Biotechnology vendor (Dallas, TX, USA). The total protein and NE-PER cytoplasmic and nuclear extraction kit was acquired from Thermo Fisher Scientific (Waltham, MA, USA). Rat TNF-α and IL-6 ELISA kits were procured from R&D Systems, Inc. (Minneapolis, MN, USA).

Animals {#s3_2}
-------

The male wistar rats, of 231--249 g, used in this study were obtained from the Central Animal Facility in King Saud University (CAF-KSU). The animals were kept, fed, and handled as the following: each plastic cage has n = 6 in a 12 h light/dark cycle at controlled temperature of 25 ± 2°C, a standard pellet diet and water *ad libitum* were fed to the rats, and all handling of the animals were correspondingly with Guide for the Care and Use of Laboratory Animals by the Animal Care Center. The Research Ethics Committee of the College of Pharmacy, King Saud University (Riyadh, Saudi Arabia, KSU‐SE‐20‐4) approved this study.

Induction of Diabetes {#s3_3}
---------------------

The 12-h fasting rats were subjected to diabetes induction using STZ with a dose of 60 mg/kg in a buffer of citric acid at pH 4.5. The route of STZ administration was intraperitoneally (i.p.) ([@B12]). After 1 h of the STZ injection, the animals were fed *ad libitum* and kept under observation for approximately 48 h. The rats were then fasted 12 h and FBG levels were examined 72 h of STZ treatment. Animals exhibiting FBG \>250 mg/dl were deliberated diabetic animals.

Experimental Design {#s3_4}
-------------------

The animals were arbitrarily separated into four categories. Group I consisted of six normal rats. The STZ-induced DN rats (Groups II--IV) were grouped into three groups (n = 6) at random. Group II served as the DN control and was administered 2 ml of normal saline per day. Groups III and IV were administered SA (20 and 40 mg/kg•bw/d, respectively). Measurements of body weight, blood glucose, and food and water consumption were taken, and physical examinations were conducted at regular intervals. Blood was collected for serum separation. Fasting blood glucose levels were assessed to confirm the anti-hyperglycemic properties of SA.

Preparation of Renal Tissue Homogenate {#s3_5}
--------------------------------------

All rat groups (Group I, Group II, Group III, and Group IV) were subjected to renal tissue harvesting perfused in ice-cold saline, homogenized in 100 mM Tris-HCl buffer (pH 7.4) with T 25 Digital ULTRA-TURRAX and centrifuged at 10,000 rpm for 10 min at 4°C. The upper layer was extracted and further used for evaluation of antioxidant enzymes and for the estimation of lipid peroxidation (MDA), renal tissue was homogenized in 1.15% KCl solution to obtain a 10% (w/v) homogenate. Total protein levels were assessed ([@B36]). Bovine serum albumin (BSA) was used as a reference.

Assessment of Renal Dysfunction {#s3_6}
-------------------------------

To assess the renal dysfunction, the levels of Serum FBG, BUN, 24 h urea protein, and Scr were estimated as described previously ([@B71]; [@B72]).

Oxidative and Antioxidant Indices {#s3_7}
---------------------------------

To estimate the oxidative stress condition, MDA levels (the most studied final product of LPO) was evaluated using thiobarbituric acid reactive substances method as described by [@B48]. The generated pink/red-colored product was measured at an absorbance of 532 nm (using spectrophotometer) against the MDA standard curve to determine the level ([@B44]). Nitric oxide (NO) was estimated according to the method described by Bryan and Grisham et al. ([@B8]). The tissue level of nitrite/nitrate was measured by ELISA kit using the Griess reaction, the absorbance was measured with a microreader, and the nitrite and nitrate concentration of homogenate was examined by comparison with the nitrite/nitrate standard reference curve. Superoxide dismutase (SOD) activity was examined as per the method by [@B67]. SOD assessment was based on the production of superoxide radicals generated by xanthine and xanthine oxidase, that react with 2 - (4- iodophynyl) - 3 (4 - nitophenol) - 5 -phenyltetra-zolium chloride to form a red formazan dye. The activity of catalase (CAT) was assessed following the method described by [@B1]. Briefly, the measurement of CAT activity was done by incubating the homogenate in H~2~O~2~ substrate; then the enzymatic reaction stopped by adding 1 ml of ammonium molybdate. The intensity of the yellow complex formed by molybdate and H~2~O~2~ was measured at 405 nm. Glutathione peroxidase (GPx) activity was assessed following the method, with slight modifications, described by [@B18]. GPx activity was measured by suspending 1 mg of protein from the homogenate in 1.6 ml of 50 mM phosphate buffer (pH 7.0), contained 0.2 mM NADPH, 1 mM GSH, and 1 UI/ml glutathione reductase; and the mixture was incubated at room temperature for 5 min. Then 100 *μ*l of 0.25 mM H~2~O~2~ was added to the mixture and initial (immediate) and final readings (after 5 min) were taken at 340 nm using spectrophotometer and assessed in the homogenized renal tissue.

Cytokine and Inflammatory Marker {#s3_8}
--------------------------------

Assessing the level TNF-α and IL-6 markers were performed in the renal tissue homogenates by ELISA kits obtained from R&D System according to manufacturer protocol. The wavelength measurement of the markers' absorbance was 450 nm.

Preparation of Total Protein, Cytosol, and Nuclear Protein {#s3_9}
----------------------------------------------------------

Renal tissue cytosol and nuclear protein were extracted using an NE-PER kit (Thermo Fisher Scientific). Immunoblots were executed as per the procedures of [@B73]. The protein of 25 µg was transferred to polyvinylidene difluoride (PVDF) membrane and blocked in a blocking buffer (4% skim milk in TBS of 1% Tween 20). Then, the membrane was incubated overnight (4°C) with antibodies against NRF2, HO-1, NF-κB (p65), and β-actin. After repeated washing steps with 1% Tween TBS and TBS, the membrane was incubated with secondary antibodies for 2 h (room temperature). Bands visualization were done using Luminata™ Western Chemiluminescent HRP Substrates (Millipore, Billerica, MA, USA) and densitometric analysis of the immunoblots (LI-COR C-Di-Git Blot Scanners, Lincoln, NE, USA).

Histological Analysis {#s3_10}
---------------------

Fixation of the renal tissues were done as the following: 10% formalin, then dehydrated with gradient alcohol and soaked in paraffin blocks. Afterward, the tissues were sliced into sections of 4 μm and stained with hematoxylin and eosin (H&E) dye and examined under a light microscope.

Statistical Analysis {#s3_11}
--------------------

The statistical significance was carried out using one-way-analysis of variance (ANOVA) and *post-hoc* with Dennett's test to determine the significant differences. All data were reported here with arithmetic means ± SEM.

Results {#s4}
=======

Our results showed 85% of the rats have type-II diabetes which was induced by STZ. These rats exhibited signs of glycosuria, polyuria, hyperglycemia, body weight loss, and water uptake enhancement. The loss of body weight (BW) in rats in comparison to normal control (NC) was considered as a sign of elevated blood sugar. Therefore, changes in the initial and final BW of the NC and STZ induced DN were observed and recorded ([**Table 1**](#T1){ref-type="table"}). SA oral administration (20 and 40 mg/kg B.W.) exhibited significant nephroprotection from considerable weight loss (p \< 0.05). The renal weight and kidney hypertrophy index in STZ-induced DN rats were significantly increased in comparison to those in the NC group. SA oral administration (20 and 40 mg/kg B.W.) to STZ-induced diabetic rats significantly ameliorated the kidney hypertrophy index ([**Table 1**](#T1){ref-type="table"}).

###### 

Initial and final body weights of rats (n = 6).

  Animals                  Initial body weight (g)   Final body weight (g)   \% gain   Renal weight (g)   Renal hypertrophy index
  ------------------------ ------------------------- ----------------------- --------- ------------------ -------------------------
  **Normal**               247.00 ± 3.50             294.83 ± 3.59           16.22     1.25 ± 0.03        0.42 ± 0.01
  **STZ-induced DN**       240.33 ± 2.22             170.33 ± 2.12           −41.10    1.49 ± 0.04        0.87 ± 0.02
  **STZ+SA 20 mg/kg bw**   243.17 ± 3.93             195.00 ± 2.85           −24.70    1.30 ± 0.03        0.66 ± 0.02
  **STZ+SA 40 mg/kg bw**   250.50 ± 3.49             212.67 ± 1.15           −17.79    1.25 ± 0.02        0.58 ± 0.01

Biochemical Findings {#s4_1}
--------------------

For assessing hyperglycemia, FBG levels were measured after 72 h of administering STZ to the rats; 87.5% of the rats were found to be diabetic with an average FBG level of 533.67 ± 3.90 mg/dl. The STZ-induced DN rats (Groups II--IV) were arbitrarily divided into three groups (n = 6). After 8 weeks of SA oral administration (20 and 40 mg/kg B.W.), these rats exhibited a significant dose-dependent reduction in FBG levels. The SA (20 and 40 mg/kg B.W.)-administered diabetic rats exhibited amelioration of hyperglycemia in a dose dependent manner, with average FBG levels of 359.40 ± 5.11 mg/dl (37.9%) for a 20 mg/kg SA dose and 294.96 ± 4.76 mg/dl (49.04%) for a 40 mg/kg SA dose. However, the average FBG level in non-treated diabetic rats was 578.83 ± 3.89 mg/dl ([**Table 2**](#T2){ref-type="table"}). Normal control rats exhibited FBG levels of 91.17 ± 2.37 at 72 h and 90.17 ± 1.92 after 8 weeks, indicating no change. We have noticed significant enhancement in the level of BUN (215.80%), 24 h urea albumin protein (208.75%), LDH (222.67%), and creatinine (151.3%) in STZ-induced diabetic rats. Oral administration of 20 and 40 mg/kg SA to diabetic rats showed significant dose-dependent reductions in BUN (35.21 and 48.88%, respectively), 24 h urea protein (33.83 and 41.57%, respectively), LDH (25.79 and 56.73%, respectively), and creatinine (28.81 and 41.47%, respectively) levels ([**Table 3**](#T3){ref-type="table"}). These significant reductions indicate the amelioration of STZ-induced DN in experimental rats.

###### 

Assessment of FBG levels in STZ-induced diabetic rats.

  Animals                  72 H (mg/dl)         8 Weeks (mg/dl)
  ------------------------ -------------------- ---------------------
  **Normal**               91.17 ± 2.37         90.17 ± 1.92
  **STZ-induced DN**       533.67 ± 3.90        578.83 ± 8.27
  **STZ+SA 20 mg/kg bw**   559.0 ± 7.34^\*\#^   359.4 ± 5.11^\*\#^
  **STZ+SA 40 mg/kg bw**   570 ± 0.03^\*\#^     294.97 ± 4.76^\*\#^

The mean ± SEM of six animals in each group were calculated. "\*" Indicates significant differences to the STZ-induced diabetic group (P value \< 0.05); "\#" indicates significant differences to the normal control.

###### 

Assessment of renal dysfunction levels in STZ-induced diabetic rats.

  Animals                  Creatinine (mg/dl)   Blood urea nitrogen (mg/dl)   LDH(nmol/l)           Total albumin 24 H (mg/day)
  ------------------------ -------------------- ----------------------------- --------------------- -----------------------------
  **Normal**               0.48 ± 0.02          20.02 ± 0.87                  64.04 ± 1.47          1.34 ± 0.15
  **STZ-induced DN**       1.21 ± 0.05          63.22 ± 1.93                  206.64 ± 4.57         2.80 ± 0.36
  **STZ+SA 20 mg/kg bw**   0.86 ± 0.03^\*\#^    40.96 ± 1.18^\*\#^            153.35 ± 3.59^\*\#^   1.85 ± 0.07^\*\#^
  **STZ+SA 40 mg/kg bw**   0.71 ± 0.03^\*\#^    32.32 ± 1.14^\*\#^            89.42 ± 2.29^\*\#^    1.64 ± 0.10^\*\#^

The mean ± SEM of six animals in each group were calculated. "\*" Indicates significant differences to the STZ-induced diabetic group (P value \< 0.05); "\#" indicates significant differences to the normal control.

Serum Lipid Profile {#s4_2}
-------------------

The serum lipid levels of TC, TG, VLDL, and LDL were evaluated in the treated STZ-DN rats with 20 and 40 mg/kg SA ([**Table 4**](#T4){ref-type="table"}). As represented in the [**Table 4**](#T4){ref-type="table"}, the levels of serum TC, TG, VLDL, and LDL were significantly augmented in diabetic rats at 204.93, 202.55, 202.69, and 661.07%, respectively, when compared to the normal ones. However, the levels of serum HDL were significantly reduced by 23.97% in DN rats, in comparison to normal ones. Also, pretreatment of 20 and 40 mg/kg SA can increase 48.63 and 32.21%. The pretreatment with a 20 mg of SA can significantly reduce TC and TG levels to 35.24 and 42.90% in comparison to STZ induced DN rats. For pretreatment with 40 mg of SA, the TC and TG levels showed 51.97 and 53.19% reduction in comparison to STZ induced DN rats. Both 20 and 40 mg pretreatments showed significant and dose dependent reduction for TC and TG. Also, the levels of VLDL and LDL in pretreatment rats were reduced significantly and, in a dose, dependent manner to 42.90 and 49.69% with pretreatment 20 mg of SA and to 53.19 and 68.28% with pretreatment 40 mg of SA, respectively.

###### 

Assessment of the serum lipid profiles in STZ-induced diabetic rats.

  Animals                  TC(mmol/L)            TG(mmol/L)           VLD(mmol/L)          LDL(mmol/L)          HDL (mmol/L)
  ------------------------ --------------------- -------------------- -------------------- -------------------- ------------------
  **Normal**               65.75 ± 3.54          63.68 ± 8.67         12.74 ± 0.53         17.76 ± 3.94         35.25 ± 2.51
  **STZ-induced DN**       200.50 ± 8.21         192.67 ± 3.55        38.53 ± 0.71         135.17 ± 8.70        26.80 ± 1.44
  **STZ+SA 20 mg/kg bw**   129.83 ± 7.55^\*\#^   110.0 ± 2.62^\*\#^   22.0 ± 0.52^\*\#^    68.0 ± 6.59^\*\#^    39.83 ± 1.93^\*^
  **STZ+SA 40 mg/kg bw**   96.33 ± 3.52^\*\#^    90.18 ± 2.04^\*\#^   18.04 ± 0.41^\*\#^   42.86 ± 3.48^\*\#^   35.43 ± 2.19^\*^

The mean ± SEM of six animals in each group were calculated. "\*" Indicates significant differences to the STZ-induced diabetic group (P value \< 0.05); "\#" indicates significant differences to the normal control.

Antioxidant Effects of SA {#s4_3}
-------------------------

As illustrated in [**Table 5**](#T5){ref-type="table"}, GPx, SOD, and catalase activities were significantly reduced to 57.34, 67.43, and 57.66%, respectively, due to depletion of antioxidant enzymes in STZ-induced diabetic rats compared to normal rats. The oral administration of 20 and 40 mg/kg SA significantly enhanced GPx, SOD, and catalase activity to 46.073 and 74.52%, 29.47 and 60.44%, and 77.34 and 108.49%, respectively, indicating the restoration of antioxidant defense enzymes.

###### 

Antioxidant effects of sinapic acid in STZ-induced diabetic rats.

  Animals                  CAT(U/mg protein)    GPX(U/mg protein)      SOD(U/mg protein)
  ------------------------ -------------------- ---------------------- --------------------
  **Normal**               12.34 ± 0.35         522.86 ± 8.67          78.87 ± 2.82
  **STZ-induced DN**       5.22 ± 0.14          203.01 ± 6.89          25.68 ± 1.59
  **STZ+SA 20 mg/kg bw**   9.26 ± 0.31^\*\#^    325.75 ± 5.23^\*\#^    33.25 ± 1.28^\*\#^
  **STZ+SA 40 mg/kg bw**   10.88 ± 0.41^\*\#^   389.21 ± 10.85^\*\#^   41.21 ± 2.04^\*\#^

The mean ± SEM of six animals in each group were calculated. "\*" Indicates significant differences to the STZ-induced diabetic group (P value \< 0.05); "\#" indicates significant differences to the normal control.

Oxidative Stress Markers MDA and NO {#s4_4}
-----------------------------------

The kidneys of STZ-treated diabetic rats exhibited significant enhancements in MDA levels (140.42%; P \< 0.05; [**Table 6**](#T6){ref-type="table"}) and NO content (78.98%; P \< 0.05; [**Table 6**](#T6){ref-type="table"}) compared to those of the normal control rats. However, the oral administration of 20 and 40 mg/kg SA significantly reduced MDA and NO2 activity to 33.70 and 46.07% (P \< 0.05 or P \< 0.05) and 15.88 and 33.79% (P \< 0.05 or P \< 0.05), respectively, indicating the abolition of oxidative stress.

###### 

Oxidative stress marker (MDA) in STZ-induced diabetic rats.

  ----------------------------------------------------------------------
  **Animals**              **NO~2~**\              **MDA**\
                           **(nmol/mg protein)**   **(ng/mg protein)**
  ------------------------ ----------------------- ---------------------
  **Normal**               29.90 ± 1.01            10.08 ± 0.71

  **STZ-induced DN**       53.52 ± 1.61            24.25 ± 1.22

  **STZ+SA 20 mg/kg bw**   45.01 ± 1.56^\*\#^      16.08 ± 0.32^\*\#^

  **STZ+SA 40 mg/kg bw**   35.43 ± 1.02^\*\#^      13.08 ± 032^\*\#^
  ----------------------------------------------------------------------

The mean ± SEM of six animals in each group were calculated. "\*" Indicates significant differences to the STZ-induced diabetic group (P value \< 0.05); "\#" indicates significant differences to the normal control.

Inflammatory Markers and Cytokines {#s4_5}
----------------------------------

The results validated that TFN-α and IL-6 was significantly enhanced in the STZ-induced diabetic kidneys at 265.66, and 248%, respectively (all P \< 0.05) compared to the control rats. Additionally, 20 and 40 mg/kg SA pretreatment significantly and dose-dependently downregulated these effects (P \< 0.05 or P \< 0.05; [**Table 7**](#T7){ref-type="table"}) to 29.69 and 50.38%, respectively, for TFN-α; 30.16 and 43.68%, respectively, for IL-6 compared to those in the STZ-induced diabetic control rats.

###### 

Assessment of cytokine and inflammatory markers in STZ-induced diabetic rats.

  Animals                  TNF-α(pg/mg protein)   IL-6(pg/mg protein)
  ------------------------ ---------------------- ---------------------
  **Normal**               28.67 ± 1.68           33.59 ± 1.38
  **STZ-induced DN**       104.83 ± 1.95          83.33 ± 4.41
  **STZ+SA 20 mg/kg bw**   73.71 ± 0.1.73^\*\#^   58.1+9 ± 2.69^\*\#^
  **STZ+SA 40 mg/kg bw**   52.01 ± 1.54^\*\#^     46.93 ± 1.79^\*\#^

The mean ± SEM of six animals in each group were calculated. "\*" Indicates significant differences to the STZ-induced diabetic group (P value \< 0.05); "\#" indicates significant differences to the normal control.

Western Blot {#s4_6}
------------

The Nrf2/HO-1 signaling pathway plays a crucial role in antioxidant reactions ([@B77]; [@B58]). To examine whether the pathway is associated with the protective effects of 20 and 40 mg/kg SA on STZ-induced oxidative nephrotoxicity, the expression of Nrf2 and HO-1 were examined ([**Figure 1**](#f1){ref-type="fig"}). Overall, 20 and 40 mg/kg SA pretreatment significantly and dose-dependently upregulated the expressions of Nrf2, HO-1, IkBα, and Bcl-2 but downregulated NF-κB, caspase 3, and Bax protein expression in renal tissue, in comparison to those in STZ-induced diabetic control rats (P \< 0.05).

![Effect of sinapic acid on the protein expression of **(A)**. Transforming growth factor-β1 (TGF-β1), **(B)** heme oxygenase-1 (HO-1), **(C)** nuclear factor erythroid 2-related factor 2 (Nrf2). The reported results are presented as the mean ± SEM of six animals per group. "\*" Indicates significant differences to the STZ-induced diabetic group (P \< 0.05); "\#" indicates significant differences to the normal control.](fphar-11-01119-g001){#f1}

Histopathological Findings {#s4_7}
--------------------------

Expansion of glomerular mesangium a key feature of DN, that is encouraged by mesangial cell proliferation and deposition of extracellular matrices as depicted in [**Figure 2**](#f2){ref-type="fig"}. Normal rats exhibit normal architecture of cortical glomerulus and mesangium without extracellular matrix deposition. SA acid 20 and 40 mg/kg administration significantly restored the cortical glomerulus and mesangium with less deposition of extracellular matrix as compared to DN rats.

![Effect of SA (20 and 40 mg/kg/day) on structural histological features of STZ-induced diabetic nephropathy (H&E). **(A)** Renal tissue of slides of normal control rats exhibits the normal architecture of the glomerulus capillaries, with both proximal convoluted tubules (PC) and distal convoluted tubules (DC) exhibiting a normal tubular epithelium (\*). **(B)** Renal tissue of slides of STZ induced diabetic rats the altered architecture glomerular capillaries are widened, irregular, and attached to the Bowman's capsule (Blue arrow) and exhibiting nodular sclerosis and necrosis (Orange arrow). The tubular epithelium is also altered (\*). **(C)** Renal tissue of slides of STZ induced diabetic rats after treatment with 20 mg SA; the altered features are moderately improved compared to normal control rats. The glomerular capillaries retain their normal size and appearance (Blue arrow), but the mesangial cell number is still relatively higher than that of normal rats (\#) and the tubular epithelium is reduced (\*). **(D)** Renal tissue of slides of STZ induced diabetic rats after treatment with 40 mg SA; the histological features impressively restored towards normalcy; there is a nearly normal structure of glomerular capillaries and Bowman capsule (Blue arrow) and tubular epithelium (\*) and exhibit minimal nodular sclerosis and necrosis (Orange arrow).](fphar-11-01119-g002){#f2}

Discussion {#s5}
==========

DM is often associated with the lethal impediment of DN, which is the key prevalent cause of terminal-stage kidney failure. Overall, 15--25% of type 1 and 30--40% of type 2 patients with DM suffer from DN ([@B20]). In this study, STZ-induced type 1 diabetes was examined to understand the DN ([@B17]; [@B51]). STZ is the most commonly used agent for inducing type 1 DM because it can trigger specific necrosis of β islets of pancreatic cells that causes degranulation and reduces their ability to discharge insulin, thus, instigating hyperglycemia and nephropathy ([@B5]). STZ-induced diabetes is frequently linked with a significant decline in BW and kidney hypertrophy index due to hyperglycemia, hypoinsulinemia, and the loss of muscles proteins ([@B12]; [@B40]). The body weight and kidney hypertrophy indices of STZ-induced DN gradually decreased and treatment with SA (20 and 40 mg/kg•bw/d) increased BW significantly, thus preventing muscle tissue loss due to hyperglycemia.

In the present study, the STZ-induced diabetic rats experienced damage to kidney functions, which were identified through the substantial elevation of BUN, 24 h urea, and creatinine levels and instability in renal histomorphological architecture, that was obvious by tubular necrosis, grave glomerular mobbing, and intertubular hemorrhage. These results are consistent with those of previous studies ([@B51]; [@B69]; [@B82]). Pretreatment with SA (20 and 40 mg/kg•bw/d) prevented the progression of DN by significantly reducing kidney function markers, such as 24 h urea protein, BUN, and creatinine, and alleviating ultrastructural changes linked with the amelioration of kidney injuries due to oxidative stress, fibrosis, and inflammation ([@B70]). Hyperglycemia induced oxidative and osmotic stress causes DN ([@B16]; [@B66]). Several *in vitro* studies have illustrated that the accumulation of ROS under hyperglycemic conditions leads to renal injuries ([@B14]; [@B19]; [@B27]). ROS accumulation substantially increased in cortical glomerulus cells, comprising endothelial, mesangial, and tubular epithelial cells under hyperglycemic conditions ([@B32]). The accumulation and overexpression of TGF-β in kidneys may lead to the development of renal hypertrophy. Protein synthesis rate increase and kidney extracellular organelle degradation reduction may also lead to renal hypertrophy. SA pretreatment abridged kidney hypertrophy indices thus, validating the reversal of renal hypertrophy in STZ-induced DN rats. Changes in oxidative stress markers (MDA) and antioxidant defense enzymes indicate oxidative stress in the cells ([@B3]; [@B50]). SA treatment significantly inhibited both nitric oxide and lipid peroxidation in STZ induced DN rats. it was reported that SA caused a reduction in renal NO levels in injured rat kidneys ([@B61]; [@B84]). [@B13] showed that NO plays a role in DN due to the free radical nature of NO that contribute to tubular injuries. NO encourages renal injury by accumulation of cytotoxic peroxynitrite that can induce tubular necrosis, resulting in DN ([@B49]).

Augmentation in lipid peroxidation and NO levels leads to oxidative stress that may cause depletion in antioxidant defense enzymes. GPX, SOD, and catalases have been implicated in STZ-induced DN in previous studies ([@B79]; [@B57]). Abovementioned data further endorsed the antioxidant potential of SA pretreatment STZ-induced DN rats. Overall, 20 and 40 mg/kg SA pretreatment of STZ-induced DN rats significantly suppressed the LPO and NO levels and replenished the normal levels of antioxidant defense enzymes in a dose-dependent scenario. The Nrf2/HO-1 pathway is a crucial cytodefense redox mechanism for dealing oxidative stress ([@B25]; [@B77]). The pathway controls intracellular phase II detoxifying enzymes to counteract ROS to encourage cellular redox steady state ([@B83]). HO-1, GPx, and NAD(P)H NQO1 are upregulated by a regulatory antioxidant element in reaction to oxidative stress ([@B9]). The augmentation of serum lipids is primarily caused by upregulation in the transport of free fatty acids from adipose deposits due to lipase production. Hence, an escalation in the free lipids levels in DN ([@B75]). The pretreatment of 20 and 40 mg/kg SA on STZ-induced DN rats tended to bring the serum lipid levels close to normal levels. SA has antihyperglycemic, antihyperlipidemic, and antioxidant activity ([@B80]; [@B61]; [@B46]; [@B47]; [@B84]; [@B85]), which may reduce how prone lipids are to oxidation and stabilize the membrane lipids, thus inhibiting oxidative stress. Therefore, SA treatments demonstrated hypo-cholesterolemic, hypo-phospholipidemic and hypo-triglyceridemic activity, but at the same time increased HDL levels. Increases in BUN, SCr, and 24 h urea protein levels in STZ-induced DN rats are markers for the progression of DN ([@B38]). Taking account of above data SA pretreatment suggests that SA acts as a nephroprotective agent against DN or delaying its progression. Patients with diabetes have increased HO-1 protein expression due to oxidative stress. The pretreatment of STZ-induced DN rats with SA upregulated the expression of HO-1 through the activation of Nrf2 expression. Apoptosis cause to renal impairment following to ischemia in DM ([@B6]; [@B54]; [@B74]; [@B31]).

Bcl-2 is a key protein that controls apoptosis in cells, and upregulation of Bcl-2 expression encourage cell survival ([@B35]; [@B23]; [@B68]; [@B76]; [@B4]). Earlier reports revealed that the upregulation of the Nrf2/HO-1 proteins has an anti-apoptosis role, and that the activation of Nrf2 could induce the expression of HO-1 to enhance the expression of Bcl-2 ([@B37]). Another study found that the downregulation in the renal expressions of HO-1, Nrf2, IKBα, and BCL2 and the upregulation of NF-kB and Bax in STZ-induced diabetic rats induced DN, which is similar to the results of the present study ([**Figure 3**](#f3){ref-type="fig"}) ([@B51]; [@B82]; [@B28]). Histological evaluation further establishes that SA pretreatment significantly ameliorates STZ-induced DN.

![Effect of sinapic acid on the protein expression of **(A)** nuclear factor kappa B (NF-kB), **(B)** IκBα protein (IkBα), **(C)** anti-apoptotic protein BCl2, **(D)** caspase 3, and **(E)** Bax in STZ-induced diabetic rats. The reported results are presented as the mean ± SEM of six animals per group. "\*" Indicates significant differences to the STZ-induced diabetic group (P \< 0.05); "\#" indicates significant differences to the normal control.](fphar-11-01119-g003){#f3}

Conclusion {#s6}
==========

This study demonstrates that SA a dietary antioxidant ameliorates oxidative stress and the progression of STZ-induced DN by regulating the gene expression of SOD, GPx, and catalase and *via* the upregulation of Nrf2/HO-1 and downregulation of NF-kB signaling pathway. Overall 20 and 40 mg/kg SA pretreatment significantly and dose-dependently upregulated the expression of Nrf2, HO-1, IKBα, and Bcl-2, and downregulated the expression of NF-κB. These results suggest that the protective mechanism of SA is due to its antioxidant and inflammatory activity wherein the release of pro-inflammatory cytokines and inflammatory markers (TNFα, IL-6, and MPO) is prevented, antioxidant defense enzymes are upregulated, and lipid peroxidation and NO production as well as anti-apoptotic activity are reduced. This is potentially influenced by the control of MPO, TNF-α, IL-6, Bcl-2, and NF-kB and BaX *via* the Nrf2/HO-1 signaling pathway on STZ-induced DN. It is suggested that SA ameliorates the progression of STZ-induced DN in rats *via* NRF2/HO-1-mediated pathways. Further studies are required to better explain the underlying mechanisms.
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